10-Q: TransCode Therapeutics Reports Q1 2025 Results, Faces Nasdaq Delisting Risk

TransCode Therapeutics reports a net loss of $12.1 million for Q1 2025 and faces potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.

Summary

• TransCode Therapeutics, a biopharmaceutical company focused on RNA therapeutics for cancer, reported its financial results for the first quarter of 2025.
• The company's net loss for the quarter was $12.1 million, compared to a net loss of $3.3 million for the same period in 2024.
• Research and development expenses increased to $2.2 million from $1.8 million year-over-year, reflecting clinical trial start-up costs.
• General and administrative expenses decreased to $952,000 from $1.5 million year-over-year.
• The company had cash of $11.6 million as of March 31, 2025, which is expected to fund operations into the fourth quarter of 2025.
• TransCode is actively pursuing additional funding through equity or debt financing.
• The company is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement and has requested a hearing to appeal the decision.
• A reverse stock split was approved in May 2025 to address the Nasdaq compliance issue.
• The company's lead therapeutic candidate, TTX-MC138, is currently in a Phase 1/II clinical trial.
• The company is also developing other preclinical solid tumor programs, including TTX-siPDL1, TTX-RIGA, and TTX-siMYC.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress with its clinical trials and has secured recent financing, the increasing net loss, limited cash runway, and potential Nasdaq delisting raise significant concerns about its financial stability and future prospects.

Positives

• The Phase 1/II clinical trial for TTX-MC138 is ongoing, with preliminary data indicating no significant safety or dose-limiting toxicities in Cohorts 1, 2, and 3.
• The company completed an equity financing in March 2025, raising approximately $8.9 million in net proceeds.
• The company is relocating R&D activities to Michigan State University and has reduced headcount to manage costs.
• Grant income increased $321 thousand in the three months ended March 31, 2025, compared to the same period in 2024.

Negatives

• TransCode Therapeutics reported a net loss of $12.1 million for Q1 2025, significantly higher than the $3.3 million loss in Q1 2024.
• The company's cash reserves of $11.6 million are projected to fund operations only into the fourth quarter of 2025.
• TransCode is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has a history of operating losses and negative cash flows.

Risks

• The company's limited cash reserves and the need for additional funding raise substantial doubt about its ability to continue as a going concern.
• The potential delisting from the Nasdaq Capital Market could significantly reduce the liquidity and value of the company's stock.
• The company's reliance on successful development and commercialization of product candidates, which is subject to numerous risks and uncertainties.
• The company's dependence on third-party vendors for manufacturing and clinical trial services.
• The company's exposure to adverse global conditions, including economic uncertainty and political instability.
• The company's exposure to cyberattacks and potential data breaches.
• The company's history of operating losses and negative cash flows.

Future Outlook

The company expects its cash to fund operations into the fourth quarter of 2025 and will require additional capital to continue operations beyond that point. The company plans to continue clinical trials for TTX-MC138 and advance the development of its product candidate pipeline.

Management Comments

• Management believes that its cash at March 31, 2025, is sufficient to fund operations and capital requirements into the fourth quarter 2025, but does not believe that existing cash will be sufficient to fund requirements for a full 12 months from the date of issuance of these financial statements.
• Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary.

Industry Context

TransCode Therapeutics operates in the competitive biopharmaceutical industry, focusing on RNA therapeutics for cancer. The company's TTX delivery platform aims to improve the delivery of RNA-based drugs to tumors, addressing a key challenge in the field. The company's lead candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability in various cancers.

Comparison to Industry Standards

• It is difficult to compare TransCode's results directly to industry standards due to its early stage of development and focus on a novel RNA delivery platform.
• Comparable companies in the RNA therapeutics space include Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which have achieved significant milestones in developing and commercializing RNAi-based drugs.
• However, these companies have different technology platforms and are at different stages of development than TransCode.
• TransCode's success will depend on the validation of its TTX delivery platform and the clinical efficacy of its lead candidate, TTX-MC138.

Legal Proceedings

• The Company is subject to claims by an investment bank that it is entitled to fees, claims which the Company rigorously disputes.

Stakeholder Impact

• Shareholders face the risk of stock dilution from future equity offerings and potential loss of investment due to the company's financial challenges and potential delisting.
• Employees may be affected by cost reduction measures, including potential layoffs.
• The company's ability to develop and commercialize its product candidates could impact cancer patients and the broader healthcare community.
• Suppliers and vendors may be affected by the company's financial challenges and potential restructuring.

Next Steps

• Continue the Phase 1/II clinical trial for TTX-MC138.
• Advance the development of other preclinical solid tumor programs.
• Seek additional funding through equity or debt financing.
• Appeal the Nasdaq delisting notice.
• Implement measures to remediate material weaknesses in internal control over financial reporting.

Key Dates

Keywords

TransCode Therapeutics, RNA therapeutics, TTX-MC138, Clinical trial, Nasdaq, Delisting, Financial results, Net loss, Reverse stock split, Biopharmaceutical